Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, MBX Biosciences Inc’s stock clocked out at $13.75, up 3.77% from its previous closing price of $13.25. In other words, the price has increased by $3.77 from its previous closing price. On the day, 0.51 million shares were traded. MBX stock price reached its highest trading level at $13.89 during the session, while it also had its lowest trading level at $12.55.
Ratios:
To gain a deeper understanding of MBX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 23.31 and its Current Ratio is at 23.31. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on July 16, 2025, initiated with a Outperform rating and assigned the stock a target price of $38.
On April 10, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $38.
On October 08, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $40.Stifel initiated its Buy rating on October 08, 2024, with a $40 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 08 ’25 when Pescovitz Ora H. bought 7,693 shares for $5.89 per share. The transaction valued at 45,312 led to the insider holds 24,329 shares of the business.
GORDON CARL L bought 143,170 shares of MBX for $1,551,963 on Feb 18 ’25. The Director now owns 3,255,000 shares after completing the transaction at $10.84 per share. On Feb 14 ’25, another insider, GORDON CARL L, who serves as the Director of the company, bought 47,502 shares for $9.87 each. As a result, the insider paid 468,793 and bolstered with 3,205,930 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MBX now has a Market Capitalization of 459585504 and an Enterprise Value of 218929104.
Stock Price History:
Over the past 52 weeks, MBX has reached a high of $27.50, while it has fallen to a 52-week low of $4.81. The 50-Day Moving Average of the stock is 11.91%, while the 200-Day Moving Average is calculated to be 1.12%.
Shares Statistics:
It appears that MBX traded 351.71K shares on average per day over the past three months and 616400 shares per day over the past ten days. A total of 33.42M shares are outstanding, with a floating share count of 14.85M. Insiders hold about 55.58% of the company’s shares, while institutions hold 54.29% stake in the company. Shares short for MBX as of 1752537600 were 4782900 with a Short Ratio of 13.60, compared to 1749772800 on 4652881. Therefore, it implies a Short% of Shares Outstanding of 4782900 and a Short% of Float of 28.77.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of MBX Biosciences Inc (MBX) is the result of assessments by 4 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.51 and low estimates of -$0.76.
Analysts are recommending an EPS of between -$2.36 and -$2.92 for the fiscal current year, implying an average EPS of -$2.68. EPS for the following year is -$2.6, with 4.0 analysts recommending between -$2.22 and -$2.96.
